BIBLIOGRAFIA

[1] M. Rizzetto et al., “Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.,” Gut, vol. 18, no. 12, pp. 997–1003, Dec. 1977, doi: 10.1136/gut.18.12.997

[2] P. Farci and G. Anna Niro, “Current and Future Management of Chronic Hepatitis D.,” Gastroenterol. Hepatol. (N. Y)., vol. 14, no. 6, pp. 342–351, Jun. 2018, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/30166948.

[3] P. Farci and G. Niro, “Clinical Features of Hepatitis D,” Semin. Liver Dis., vol. 32, no. 03, pp. 228–236, Aug. 2012, doi: 10.1055/s-0032-1323628.

[4] F. Negro, “Hepatitis D Virus Coinfection and Superinfection,” Cold Spring Harb. Perspect. Med., vol. 4, no. 11, pp. a021550–a021550, Nov. 2014, doi: 10.1101/cshperspect.a021550.

[5] WHO, “Hepatitis D.” https://www.who.int/news-room/fact-sheets/detail/hepatitis-d.

[6] A. J. Stockdale et al., “The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis,” J. Hepatol., vol. 73, no. 3, pp. 523–532, Sep. 2020, doi: 10.1016/j.jhep.2020.04.008.

[7] H. Wedemeyer and M. P. Manns, “Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead,” Nat. Rev. Gastroenterol. Hepatol., vol. 7, no. 1, pp. 31–40, Jan. 2010, doi: 10.1038/nrgastro.2009.205.

[8] M. Rizzetto, S. Hamid, and F. Negro, “The changing context of hepatitis D,” J. Hepatol., vol. 74, no. 5, pp. 1200–1211, May 2021, doi: 10.1016/j.jhep.2021.01.014.

[9] J. Grabowski and H. Wedemeyer, “Hepatitis Delta: Immunopathogenesis and Clinical Challenges,” Dig. Dis., vol. 28, no. 1, pp. 133–138, 2010, doi: 10.1159/000282076.

[10] P. Piantino, “Markers tumorali in gastroenterologia,” no. Markers tumorali in gastroenterologia, 1988.

[11] P. R. . Rizzetto M;, Verme G., Gerin J.L., Hepatitis delta virus disease. New York: Progress in liver disease. Vol. VIII., 1986.

[12] S. A. Rizzetto M., Ponzetto A., Bonino F., Hepatitis Delta virus infection: clinical and epidemiological aspects, Viral Hepa. New York, 1988.

[13] S. Govindarajan, B. Valinluck, and L. Peters, “Relapse of acute B viral hepatitis--role of delta agent.,” Gut, vol. 27, no. 1, pp. 19–22, Jan. 1986, doi: 10.1136/gut.27.1.19.

[14] M. Aragona et al., “SEROLOGICAL RESPONSE TO THE HEPATITIS DELTA VIRUS IN HEPATITIS D,” Lancet, vol. 329, no. 8531, pp. 478–480, Feb. 1987, doi: 10.1016/S0140-6736(87)92090-3.

[15] Y.-H. HUANG, J.-C. WU, W.-Y. SHENG, T.-I. HUO, F.-Y. CHANG, and S.-D. LEE, “Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: A study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction,” J. Gastroenterol. Hepatol., vol. 13, no. 1, pp. 57–61, Jan. 1998, doi: 10.1111/j.1440-1746.1998.tb00546.x.

[16] P. Farci et al., “Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity.,” Gastroenterology, vol. 85, no. 3, pp. 669–73, Sep. 1983, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/6873613.

[17] G. Raimondo, G. Longo, and G. Squadrito, “Exacerbation of chronic liver disease due to hepatitis B surface antigen after delta infection.,” BMJ, vol. 286, no. 6368, pp. 845–845, Mar. 1983, doi: 10.1136/bmj.286.6368.845.

[18] J.-C. Wu et al., “Natural history of hepatitis D viral superinfection: Significance of viremia detected by polymerase chain reaction,” Gastroenterology, vol. 108, no. 3, pp. 796–802, Mar. 1995, doi: 10.1016/0016-5085(95)90453-0.

[19] I. TAMURA et al., “Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: A study from Kure, Japan,” J. Gastroenterol. Hepatol., vol. 8, no. 5, pp. 433–436, Oct. 1993, doi: 10.1111/j.1440-1746.1993.tb01543.x.

[20] R. Romeo et al., “A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma,” Gastroenterology, vol. 136, no. 5, pp. 1629–1638, May 2009, doi: 10.1053/j.gastro.2009.01.052.

[21] G. Fattovich et al., “Influence of Hepatitis Delta Virus Infection on Progression to Cirrhosis in Chronic Hepatitis Type B,” J. Infect. Dis., vol. 155, no. 5, pp. 931–935, May 1987, doi: 10.1093/infdis/155.5.931.

[22] G. Fattovich, “Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B,” Gut, vol. 46, no. 3, pp. 420–426, Mar. 2000, doi: 10.1136/gut.46.3.420.

[23] A. U. Toukan et al., “The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan,” Hepatology, vol. 7, no. 6, pp. 1340–1345, Nov. 1987, doi: 10.1002/hep.1840070627.

[24] T. Kushner, M. Serper, and D. E. Kaplan, “Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes,” J. Hepatol., vol. 63, no. 3, pp. 586–592, Sep. 2015, doi: 10.1016/j.jhep.2015.04.025.

[25] J. Ji, K. Sundquist, and J. Sundquist, “A Population-Based Study of Hepatitis D Virus as Potential Risk Factor for Hepatocellular Carcinoma,” JNCI J. Natl. Cancer Inst., vol. 104, no. 10, pp. 790–792, May 2012, doi: 10.1093/jnci/djs168.

[26] Z. Abbas, “Hepatitis D and hepatocellular carcinoma,” World J. Hepatol., vol. 7, no. 5, p. 777, 2015, doi: 10.4254/wjh.v7.i5.777.

[27] T. Datfar, M. Doulberis, A. Papaefthymiou, I. N. Hines, and G. Manzini, “Viral Hepatitis and Hepatocellular Carcinoma: State of the Art,” Pathogens, vol. 10, no. 11, p. 1366, Oct. 2021, doi: 10.3390/pathogens10111366.

[28] S. Coghill, J. McNamara, M. Woods, and K. Hajkowicz, “Epidemiology and clinical outcomes of hepatitis delta (D) virus infection in Queensland, Australia,” Int. J. Infect. Dis., vol. 74, pp. 123–127, Sep. 2018, doi: 10.1016/j.ijid.2018.07.005.

[29] C. Béguelin et al., “Hepatitis delta-associated mortality in HIV/HBV-coinfected patients,” J. Hepatol., vol. 66, no. 2, pp. 297–303, Feb. 2017, doi: 10.1016/j.jhep.2016.10.007.

[30] G. A. Niro et al., “Outcome of chronic delta hepatitis in Italy: A long-term cohort study,” J. Hepatol., vol. 53, no. 5, pp. 834–840, Nov. 2010, doi: 10.1016/j.jhep.2010.06.008.

[31] M. Buti et al., “Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study,” J. Viral Hepat., vol. 18, no. 6, pp. 434–442, Jun. 2011, doi: 10.1111/j.1365-2893.2010.01324.x.

[32] A. Wranke et al., “Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN),” Liver Int., vol. 38, no. 5, pp. 842–850, May 2018, doi: 10.1111/liv.13604.

[33] C. Su et al., “Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients,” Gastroenterology, vol. 130, no. 6, pp. 1625–1635, May 2006, doi: 10.1053/j.gastro.2006.01.035.

[34] A. Wranke et al., “Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta,” PLoS One, vol. 9, no. 7, p. e101002, Jul. 2014, doi: 10.1371/journal.pone.0101002.

[35] N. Mentha, S. Clément, F. Negro, and D. Alfaiate, “A review on hepatitis D: From virology to new therapies,” J. Adv. Res., vol. 17, pp. 3–15, May 2019, doi: 10.1016/j.jare.2019.03.009.

[36] B. Coco et al., “Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort,” Dig. Liver Dis., vol. 54, pp. S15–S16, Mar. 2022, doi: 10.1016/j.dld.2022.01.030.

[37] E. Sagnelli et al., “The epidemiology of hepatitis delta infection in Italy,” J. Hepatol., vol. 15, no. 1–2, pp. 211–215, May 1992, doi: 10.1016/0168-8278(92)90038-Q.

[38] E. Sagnelli et al., “Decrease in HDV endemicity in Italy,” J. Hepatol., vol. 26, no. 1, pp. 20–24, Jan. 1997, doi: 10.1016/S0168-8278(97)80004-9.

[39] G. Gaeta, “Chronic Hepatitis D: A Vanishing Disease? An Italian Multicenter Study,” Hepatology, vol. 32, no. 4, pp. 824–827, Oct. 2000, doi: 10.1053/jhep.2000.17711.

[40] Z. Miao et al., “Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection,” J. Infect. Dis., vol. 221, no. 10, pp. 1677–1687, Apr. 2020, doi: 10.1093/infdis/jiz633.

[41] D.-T. Shen, D.-Z. Ji, H.-Y. Chen, H. Goyal, S. Pan, and H.-G. Xu, “Hepatitis D: not a rare disease anymore: global update for 2017–2018,” Gut, vol. 69, no. 4, pp. 786–788, Apr. 2020, doi: 10.1136/gutjnl-2019-318691.

[42] L. L. Gustafsson, B. Schildt, and K. Jacobsen, “Adverse effects of extradural and intrathecal opiates: report of a nationwide survey in Sweden.,” Br. J. Anaesth., vol. 54, no. 5, pp. 479–86, May 1982, doi: 10.1093/bja/54.5.479.

[43] A. Turcanu et al., “Profile of hepatocellular carcinoma in the Republic of Moldova: first-hand information on the presentation, distribution and etiologies,” Rom. J. Intern. Med., vol. 57, no. 1, pp. 37–46, Mar. 2019, doi: 10.2478/rjim-2018-0026.

[44] L. Gheorghe et al., “Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors,” J. Gastrointest. Liver Dis., vol. 24, no. 4, pp. 413–421, Dec. 2015, doi: 10.15403/jgld.2014.1121.244.dtv.

[45] M. Rizzetto and S. Hamid, “The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal,” Liver Int., vol. 41, no. 1, pp. 16–19, Jan. 2021, doi: 10.1111/liv.14729.

[46] P. A. Shah, S. Choudhry, K. J. C. Reyes, and D. T. Y. Lau, “An update on the management of chronic hepatitis D,” Gastroenterol. Rep., vol. 7, no. 6, pp. 396–402, Dec. 2019, doi: 10.1093/gastro/goz052.

[47] C. Koh, T. Heller, and J. S. Glenn, “Pathogenesis of and New Therapies for Hepatitis D,” Gastroenterology, vol. 156, no. 2, pp. 461-476.e1, Jan. 2019, doi: 10.1053/j.gastro.2018.09.058.

[48] H. Sharafi, M. S. Rezaee-Zavareh, S. M. Miri, and S. M. Alavian, “Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review,” Hepat. Mon., vol. 20, no. 2, Mar. 2020, doi: 10.5812/hepatmon.102268.

[49] J.-C. Wu, “Functional and Clinical Significance of Hepatitis D Virus Genotype II Infection,” in Hepatitis Delta Virus, Springer Berlin Heidelberg, pp. 173–186.

[50] M. Spaan et al., “Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1,” J. Hepatol., vol. 72, no. 6, pp. 1097–1104, Jun. 2020, doi: 10.1016/j.jhep.2019.12.028.

[51] M. Rizzetto, “Hepatitis D Virus: Introduction and Epidemiology,” Cold Spring Harb. Perspect. Med., vol. 5, no. 7, p. a021576, Jul. 2015, doi: 10.1101/cshperspect.a021576.

[52] T. Stroffolini et al., “Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium,” J. Viral Hepat., vol. 27, no. 9, pp. 941–947, Sep. 2020, doi: 10.1111/jvh.13310.

[53] G. U. R. Italiana, “Obbligatorieta’ della vaccinazione contro l’epatite virale B. (GU Serie Generale n.127 del 01-06-1991),” 1991. https://www.gazzettaufficiale.it/eli/id/1991/06/01/091G0201/sg.

[54] T. Stroffolini et al., “Acute Delta Hepatitis in Italy spanning three decades (1991–2019): Evidence for the effectiveness of the hepatitis B vaccination campaign,” J. Viral Hepat., vol. 29, no. 1, pp. 78–86, Jan. 2022, doi: 10.1111/jvh.13620.

[55] G. Brancaccio et al., “The present profile of chronic hepatitis B virus infection highlights future challenges,” Dig. Liver Dis., vol. 51, no. 3, pp. 438–442, Mar. 2019, doi: 10.1016/j.dld.2018.09.008.

[56] “La Piattaforma Italiana per lo Studio della Terapia delle Epatiti Virali.” https://www.progettopiter.it (accessed Apr. 28, 2022).

[57] R. Adam et al., “2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation,” Transpl. Int., vol. 31, no. 12, pp. 1293–1317, Dec. 2018, doi: 10.1111/tri.13358.

[58] G. Brancaccio, A. Vitale, G. Signoriello, G. B. Gaeta, and U. Cillo, “Changing indications for liver transplant: slow decline of hepatitis viruses in Italy,” Infect. Dis. (Auckl)., vol. 52, no. 8, pp. 557–562, Aug. 2020, doi: 10.1080/23744235.2020.1763453.

[59] J.-H. Bockmann et al., “High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort,” BMC Gastroenterol., vol. 20, no. 1, p. 24, Dec. 2020, doi: 10.1186/s12876-020-1168-9.

[60] D. Roulot et al., “Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta,” J. Hepatol., vol. 73, no. 5, pp. 1046–1062, Nov. 2020, doi: 10.1016/j.jhep.2020.06.038.

[61] M. Noureddin and R. Gish, “Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery,” Curr. Gastroenterol. Rep., vol. 16, no. 1, p. 365, Jan. 2014, doi: 10.1007/s11894-013-0365-x.

[62] G. Fattovich, “Natural History and Prognosis of Hepatitis B,” Semin. Liver Dis., vol. 23, no. 1, pp. 047–058, 2003, doi: 10.1055/s-2003-37590.

[63] R. H. Westbrook and G. Dusheiko, “Natural history of hepatitis C,” J. Hepatol., vol. 61, no. 1, pp. S58–S68, Nov. 2014, doi: 10.1016/j.jhep.2014.07.012.

[64] P. Axley, S. Mudumbi, S. Sarker, Y.-F. Kuo, and A. Singal, “Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications,” PLoS One, vol. 13, no. 5, p. e0197117, May 2018, doi: 10.1371/journal.pone.0197117.

[65] H. Kamal et al., “Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes,” Hepatology, vol. 72, no. 4, pp. 1177–1190, Oct. 2020, doi: 10.1002/hep.31214.

[66] G. Garcia-Tsao, A. J. Sanyal, N. D. Grace, and W. Carey, “Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis,” Hepatology, vol. 46, no. 3, pp. 922–938, Sep. 2007, doi: 10.1002/hep.21907.

[67] E. A. Tsochatzis, J. Bosch, and A. K. Burroughs, “Liver cirrhosis,” Lancet, vol. 383, no. 9930, pp. 1749–1761, May 2014, doi: 10.1016/S0140-6736(14)60121-5.

[68] C. Yurdaydın, R. Idilman, H. Bozkaya, and A. M. Bozdayi, “Natural history and treatment of chronic delta hepatitis,” J. Viral Hepat., vol. 17, no. 11, pp. 749–756, Nov. 2010, doi: 10.1111/j.1365-2893.2010.01353.x.

[69] M. Puigvehí, C. Moctezuma-Velázquez, A. Villanueva, and J. M. Llovet, “The oncogenic role of hepatitis delta virus in hepatocellular carcinoma,” JHEP Reports, vol. 1, no. 2, pp. 120–130, Aug. 2019, doi: 10.1016/j.jhepr.2019.05.001.

[70] M. Pinter, M. Trauner, M. Peck-Radosavljevic, and W. Sieghart, “Cancer and liver cirrhosis: implications on prognosis and management,” ESMO Open, vol. 1, no. 2, p. e000042, 2016, doi: 10.1136/esmoopen-2016-000042.

[71] P. Angeli et al., “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis,” J. Hepatol., vol. 69, no. 2, pp. 406–460, Aug. 2018, doi: 10.1016/j.jhep.2018.03.024.

[72] D. Alfaiate, S. Clément, D. Gomes, N. Goossens, and F. Negro, “Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies,” J. Hepatol., vol. 73, no. 3, pp. 533–539, Sep. 2020, doi: 10.1016/j.jhep.2020.02.030.

[73] AIRTUM-AIOM, “I numeri del cancro in Italia,” 2020.

[74] P. Golabi, S. Fazel, M. Otgonsuren, M. Sayiner, C. T. Locklear, and Z. M. Younossi, “Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities,” Medicine (Baltimore)., vol. 96, no. 9, p. e5904, Mar. 2017, doi: 10.1097/MD.0000000000005904.

[75] B. Karaman, B. Battal, S. Sari, and S. Verim, “Hepatocellular carcinoma review: Current treatment, and evidence-based medicine,” World J. Gastroenterol., vol. 20, no. 47, pp. 18059–18060, Dec. 2014, doi: 10.3748/wjg.v20.i47.18059.

[76] R. RANSFORD, “Effect on outcome of the lengthening waiting list for liver transplantation,” Gut, vol. 47, no. 3, pp. 441–443, Sep. 2000, doi: 10.1136/gut.47.3.441.

[77] W. R. Kim et al., “Deaths on the liver transplant waiting list: An analysis of competing risks,” Hepatology, vol. 43, no. 2, pp. 345–351, Feb. 2006, doi: 10.1002/hep.21025.

[78] H. Muhammad, A. Tehreem, M. B. Hammami, P.-S. Ting, R. Idilman, and A. Gurakar, “Hepatitis D virus and liver transplantation: Indications and outcomes,” World J. Hepatol., vol. 13, no. 3, pp. 291–299, Mar. 2021, doi: 10.4254/wjh.v13.i3.291.

[79] A. Ferrarese et al., “Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting,” Aliment. Pharmacol. Ther., vol. 51, no. 4, pp. 482–483, Feb. 2020, doi: 10.1111/apt.15619.

[80] A. Ottobrelli et al., “Patterns of hepatitis delta virus reinfection and disease in liver transplantation,” Gastroenterology, vol. 101, no. 6, pp. 1649–1655, Dec. 1991, doi: 10.1016/0016-5085(91)90404-9.

[81]       L. Hansen, Y. Yan, and S. J. Rosenkranz, “The Power of The Liver Transplant Waiting List: A Case Presentation,” Am. J. Crit. Care, vol. 23, no. 6, pp. 510–515, Nov. 2014, doi: 10.4037/ajcc2014399.

[82] P. Husen et al., “Risk Factors for High Mortality on the Liver Transplant Waiting List in Times of Organ Shortage: A Single-Center Analysis,” Ann. Transplant., vol. 24, pp. 242–251, May 2019, doi: 10.12659/AOT.914246.

[83] M. Clinic, “Liver Transplantation.” https://www.mayoclinic.org/tests-procedures/liver-transplant/about/pac-20384842.

[84] Z. Abbas, M. S. Memon, H. Mithani, W. Jafri, and S. Hamid, “Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience,” Antivir. Ther., vol. 19, no. 5, pp. 463–468, 2014, doi: 10.3851/IMP2728.

[85] H. Wedemeyer et al., “Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta,” N. Engl. J. Med., vol. 364, no. 4, pp. 322–331, Jan. 2011, doi: 10.1056/NEJMoa0912696.

[86] B. Heidrich et al., “Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta,” Hepatology, vol. 60, no. 1, pp. 87–97, Jul. 2014, doi: 10.1002/hep.27102.

[87] F. Bonino, K. H. Heermann, M. Rizzetto, and W. H. Gerlich, “Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope,” J. Virol., vol. 58, no. 3, pp. 945–950, Jun. 1986, doi: 10.1128/jvi.58.3.945-950.1986.

[88] K. F. Bergmann and J. L. Gerin, “Antigens of Hepatitis Delta Virus in the Liver and Serum of Humans and Animals,” J. Infect. Dis., vol. 154, no. 4, pp. 702–706, Oct. 1986, doi: 10.1093/infdis/154.4.702.

[89] M. Rizzetto, D. Gocke, G. Verme, J.-K. Shih, R. Purcell, and J. Gerin, “INCIDENCE AND SIGNIFICANCE OF ANTIBODIES TO DELTA ANTIGEN IN HEPATITIS B VIRUS INFECTION,” Lancet, vol. 314, no. 8150, pp. 986–990, Nov. 1979, doi: 10.1016/S0140-6736(79)92561-3.

[90] M. Rizzetto, J. W. Shih, and J. L. Gerin, “The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen.,” J. Immunol., vol. 125, no. 1, pp. 318–24, Jul. 1980, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/6769999.

[91] A. Smedile et al., “Riboprobe assay for HDV RNA: A sensitive method for the detection of the HDV genome in clinical serum samples,” J. Med. Virol., vol. 30, no. 1, pp. 20–24, Jan. 1990, doi: 10.1002/jmv.1890300105.

[92] E. St. Öcklin et al., “δ antigen in hepatitis B: Immunohistology of frozen and paraffin-embedded liver biopsies and relation to HBV infection,” Hepatology, vol. 1, no. 3, pp. 238–242, May 1981, doi: 10.1002/hep.1840010308.

[93] P. Farci, “Delta hepatitis: an update,” J. Hepatol., vol. 39, pp. 212–219, Jan. 2003, doi: 10.1016/S0168-8278(03)00331-3.

[94] A. SMEDILE et al., “EPIDEMIOLOGIC PATTERNS OF INFECTION WITH THE HEPATITIS B VIRUS-ASSOCIATED DELTA AGENT IN ITALY,” Am. J. Epidemiol., vol. 117, no. 2, pp. 223–229, Feb. 1983, doi: 10.1093/oxfordjournals.aje.a113533.

[95] “ELENCO MALATTIE E CONDIZIONI CRONICHE E INVALIDANTI; 18-3-2017 Supplemento ordinario n. 15 alla GAZZETTA UFFICIALE Serie generale - n. 65.” https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=18/03/2017&redaz=17A02015&artp=13&art=1&subart=1&subart1=10&vers=1&prog=001

[96] P. Lampertico et al., “EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,” J. Hepatol., vol. 67, no. 2, pp. 370–398, Aug. 2017, doi: 10.1016/j.jhep.2017.03.021.

[97] O. Etzion et al., “PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection,” J. Hepatol., vol. 70, no. 1, p. e32, Apr. 2019, doi: 10.1016/S0618-8278(19)30058-1.

[98] EMA, “Hepcludex (bulevirtide) Sintesi di Hepcludex e perché è autorizzato nell’Unione europea (UE).” https://www.ema.europa.eu/en/documents/overview/hepcludex-epar-medicine-overview_it.pdf

[99] C. Koh et al., “Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial,” Lancet Infect. Dis., vol. 15, no. 10, pp. 1167–1174, Oct. 2015, doi: 10.1016/S1473-3099(15)00074-2.

[100] ClinicalTrials.gov, “Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR).” https://clinicaltrials.gov/ct2/show/NCT03719313?term=Lonafarnib&map_cntry=IT&draw=2&rank=1.

Partecipa al sondaggio sull’epatite Delta

link al forum HBV